Organon (OGN) | Financial Analysis & Statements

Organon & Co. | Mid-cap | Healthcare

$9.72

-2.41%

Organon vs Eli Lilly and Organon vs Johnson & Johnson Organon vs AbbVie Organon vs Merck & Co Organon vs Amgen Organon vs S&P 500 | Market

Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 6.4B

Gross Profit 3.7B 58.02%

Operating Income 1.5B 23.21%

Net Income 864.0M 13.49%

EPS (Diluted) $3.33

Balance Sheet Metrics

Total Assets 13.1B

Total Liabilities 12.6B

Shareholders Equity 472.0M

Debt to Equity 26.76

Cash Flow Metrics

Operating Cash Flow 1.1B

Free Cash Flow 588.0M

Revenue & Profitability Trend

Organon Income Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Revenue	6.4B	6.3B	6.2B	6.3B	6.5B
Cost of Goods Sold	2.7B	2.5B	2.3B	2.4B	2.1B
Gross Profit	3.7B	3.7B	3.9B	3.9B	4.4B
Operating Expenses	2.2B	2.4B	2.2B	2.0B	1.6B
Operating Income	1.5B	1.3B	1.7B	1.9B	2.8B
Pre-tax Income	807.0M	673.0M	1.1B	1.5B	2.8B
Income Tax	-57.0M	-350.0M	205.0M	178.0M	496.0M
Net Income	864.0M	1.0B	917.0M	1.4B	2.2B
EPS (Diluted)	$3.33	$3.99	$3.59	$5.31	$8.53

Income Statement Trend

Organon Balance Sheet From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Assets
Current Assets	4.3B	4.5B	3.9B	3.8B	3.6B
Non-Current Assets	8.8B	7.6B	7.0B	6.9B	6.5B
Total Assets	13.1B	12.1B	11.0B	10.7B	10.1B
Liabilities
Current Liabilities	2.7B	2.9B	2.5B	2.6B	2.7B
Non-Current Liabilities	9.9B	9.2B	9.3B	9.6B	2.0B
Total Liabilities	12.6B	12.1B	11.8B	12.2B	4.6B
Equity
Total Shareholders Equity	472.0M	-70.0M	-892.0M	-1.5B	5.5B

Balance Sheet Composition

Organon Cash Flow Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Operating Activities
Net Income	864.0M	1.0B	917.0M	1.4B	2.3B
Operating Cash Flow	1.1B	641.0M	688.0M	1.9B	2.4B
Investing Activities
Capital Expenditures	4.0M	1.0M	7.0M	7.0M	5.0M
Investing Cash Flow	-162.0M	1.0M	7.0M	7.0M	5.0M
Financing Activities
Dividends Paid	-297.0M	-294.0M	-290.0M	-145.0M	0
Financing Cash Flow	-368.0M	-569.0M	-433.0M	-2.5B	-2.0B
Free Cash Flow	588.0M	538.0M	431.0M	2.0B	1.9B

Cash Flow Trend

Organon Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 3.39

Forward P/E 2.30

Price to Book 4.64

Price to Sales 0.40

PEG Ratio 2.30

Profitability Ratios

Profit Margin 11.92%

Operating Margin 21.48%

Return on Equity 254.24%

Return on Assets 6.98%

Financial Health

Current Ratio 1.67

Debt to Equity 1,652.40

Beta 0.54

Per Share Data

EPS (TTM) $2.88

Book Value per Share $2.10

Revenue per Share $24.43

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
ogn	2.5B	3.39	4.64	254.24%	11.92%	1,652.40
Eli Lilly and	691.8B	62.76	46.33	77.28%	22.67%	243.61
Johnson & Johnson	364.1B	16.83	4.66	29.45%	24.42%	66.90
AbbVie	324.6B	78.87	228.56	88.40%	7.31%	4,789.60
Merck & Co	198.5B	11.49	4.12	39.29%	27.27%	71.99
Amgen	146.5B	24.84	23.60	105.67%	17.39%	924.46

Financial data is updated regularly. All figures are in the company's reporting currency.